Business Context and Reporting Period
This Form 8-K is a current report filed by Pro-Pharmaceuticals, Inc. (not Galectin Therapeutics Inc.) on May 29, 2008. The report details corporate governance actions taken at the annual meeting of stockholders held on May 21, 2008.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure amendment and does not contain financial performance data.
Material Changes
- Authorized Share Increase: Stockholders approved an amendment to the Articles of Incorporation increasing the number of authorized shares of common stock from 100,000,000 to 200,000,000.
- Effective Date: The Certificate of Amendment was filed with the Nevada Secretary of State and became effective on May 29, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly procedural regarding the share authorization increase.
Investor Verification Checklist
- Verify the company name is Pro-Pharmaceuticals, Inc., not Galectin Therapeutics Inc.
- Confirm the new authorized share count is 200,000,000.
- Review the attached Exhibit 3.1 (Certificate of Amendment) for specific legal terms of the increase.
- Note that no financial results or operational updates are included in this specific filing.